Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-ex...
TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and ...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 ...
Financial Results Year End 2023 Tempest ended the year with $39.2 million in cash and cash equivalents, compared to $31.2 m...
Scotiabank analyst George Farmer initiates coverage on Tempest Therapeutics (NASDAQ:TPST) with a Sector Outperform rating an...
Scotiabank analyst George Farmer initiates coverage on Tempest Therapeutics (NASDAQ:TPST) with a Sector Outperform rating an...
HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 p...
Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune...
